Outcome description
| Category . | n (%)/median (IQR)/ probability (95% CI) . |
|---|---|
| Response to IST*(first line) | |
| CR/PR | 141 (69) |
| NR | 62 (30) |
| Secondary PNH from IAA | 28 (10) |
| Time to secondary PNH, mo | 42.2 (23.4-80.4) |
| CIF of secondary PNH at 10 y | 12.3 (7.8-17.8) |
| Progression to AML/MDS | 32 (12) |
| CIF of progression to AML/MDS at 10 y | 14 (10.5-19.6) |
| Time to progression AML/MDS, mo | 44.6 (24.3-77.8) |
| Follow up, mo | 85 (40-15.3) |
| Category . | n (%)/median (IQR)/ probability (95% CI) . |
|---|---|
| Response to IST*(first line) | |
| CR/PR | 141 (69) |
| NR | 62 (30) |
| Secondary PNH from IAA | 28 (10) |
| Time to secondary PNH, mo | 42.2 (23.4-80.4) |
| CIF of secondary PNH at 10 y | 12.3 (7.8-17.8) |
| Progression to AML/MDS | 32 (12) |
| CIF of progression to AML/MDS at 10 y | 14 (10.5-19.6) |
| Time to progression AML/MDS, mo | 44.6 (24.3-77.8) |
| Follow up, mo | 85 (40-15.3) |
Data reported for the Cleveland Clinic cohort only.
AML, acute myeloid leukemia; CI, confidence interval; CIF, cumulative incidence function; CR, complete response; IQR, interquartile range; IST, immunosuppressive treatment; MDS, myelodysplastic syndrome; NR, no response; PR, partial response.
Missing data.